Suki, the ambient AI scribe company that records and transcribes doctor-patient conversations into clinical notes, announced a $90 million Series E led by Healthier Capital. The round follows an earlier $70 million Series D and brings Suki’s total funding past $255 million, the company said, as it scales to roughly 450 health system and clinic customers and projects between $60 million and $80 million in 2026 revenue.
The Problem Suki Is Selling Against
Physician burnout tied to electronic health record documentation has been one of the most persistently cited crises in American medicine for a decade, with surveys repeatedly showing doctors spending one to two hours on notes and paperwork for every hour of direct patient time. Suki’s pitch is straightforward: a clinician dictates or simply talks naturally during a visit, and the software generates a structured clinical note, coded and formatted for the EHR, within minutes. The company says its tool now also handles tasks beyond note-taking, including pulling up patient history and drafting referral letters, positioning itself as a broader “AI assistant” rather than a single-purpose transcription tool.
A Crowded, Fast-Growing Category
Suki competes directly with Microsoft-owned Nuance’s DAX Copilot and Abridge, which has separately landed large health-system contracts including a multi-year Department of Veterans Affairs deal reported to be worth up to $775.72 million across vendors. Ambient scribe tools have become one of the fastest-adopted categories in clinical AI precisely because they sit alongside existing workflows rather than requiring hospitals to change how care is delivered — a lower-friction sell than diagnostic or triage AI, which often requires new clinical protocols.
Why Healthier Capital Led the Round
Healthier Capital, a growth-stage health tech investment firm, leading Suki’s round rather than a traditional venture fund reflects the same pattern seen across clinical AI financing this year: investors are increasingly underwriting these companies on recurring revenue and customer retention metrics rather than pure technology promise. Suki’s disclosed 450-customer base and specific revenue guidance — unusually precise figures for a still-private health tech company — appear calibrated to reassure growth investors that the company has moved past the pilot-program phase common to earlier clinical AI rounds.
What Doctors Say Changes Day to Day
Clinicians using ambient scribe tools consistently report the biggest change is time: notes that used to require typing after hours, during so-called “pajama time,” get mostly finished during or immediately after the visit. Health systems piloting these tools often cite reduced after-hours EHR time as their primary adoption metric, since it maps directly onto physician retention, a top financial concern for hospitals already short on clinical staff.
The Accuracy and Liability Questions
Skeptics of ambient AI scribes point to a less-discussed risk: a note is a legal and billing document, not just a convenience, and an AI-generated transcription error that misstates a symptom, dosage or diagnosis can carry real clinical and liability consequences. Most vendors, including Suki, require a physician to review and sign off on every AI-generated note before it enters the record, but critics argue that review step can become perfunctory once clinicians learn to trust the tool, potentially allowing subtle errors to slip through unchecked over time. There is also limited independent, peer-reviewed research on error rates across ambient scribe products industry-wide, with most performance data coming from vendor-sponsored studies.
The Pricing Pressure Ahead
As more vendors chase the same pool of health systems, pricing has become a growing point of competition, with hospitals increasingly able to play Suki, Abridge and Microsoft’s Nuance against one another during contract renewals. That dynamic puts pressure on margins across the category precisely as investors like Healthier Capital are underwriting these companies on growth and retention metrics, a tension that will likely sharpen as the market matures beyond its current rapid-adoption phase into a more price-sensitive, consolidation-driven one.
What’s Next
With funding secured and a customer base approaching 500 health systems, Suki’s next test is whether it can defend pricing and market share as Abridge, Microsoft and a wave of newer entrants chase the same hospitals. Expect continued consolidation in the ambient-scribe category over the next year, as health systems that ran multiple pilot programs during the technology’s early adoption phase settle on a single vendor contract, and as regulators and malpractice insurers begin paying closer attention to how AI-assisted documentation affects liability exposure.
Photo: Imad Clicks / PEXELS via Pexels
